about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

As sick­le cell pa­tients find new op­tions, NEA-found­ed Imara pitch­es mid-stage al­ter­na­tive for $86M IPO

6 years ago
Financing

Chi­na ap­proves flu drug be­ing tout­ed as a po­ten­tial coro­n­avirus treat­ment amid a rush of clin­i­cal stud­ies

6 years ago
China
Coronavirus

New en­tries, price hikes spur changes among the 20 most ex­pen­sive drugs — though not the kind politi­cians like to ...

6 years ago
Pharma

As­traZeneca's Chi­nese in­vest­ment bank part­ner rais­es $229M for its own new fund — and it's all about the ...

6 years ago
R&D
Coronavirus

8 years af­ter its OK, Ei­sai yanks its flail­ing obe­si­ty drug from the mar­ket af­ter FDA flagged high­er can­cer rate

6 years ago
Pharma
FDA+

Roche scores its first PD-L1 win in Chi­na, go­ing straight for SCLC niche

6 years ago
China
Pharma

Bris­tol-My­ers checks off an­oth­er mile­stone on the Cel­gene CVR, hus­tling Yescar­ta ri­val to the mar­ket

6 years ago
R&D

The RAS rush: Rev­o­lu­tion Med­i­cines bags re­mark­able $238M IPO raise, more than dou­bling orig­i­nal goal

6 years ago
Financing

Pre­vail's gene ther­a­py scores or­phan, rare pe­di­atric dis­ease priv­i­leges; Ger­many's ITM se­cures €40M loan

6 years ago
News Briefing

Catch­ing up with Roche, Mer­ck racks up pos­i­tive da­ta in front­line triple neg­a­tive breast can­cer

6 years ago
R&D
Pharma

Lig­and buys its way in­to part­ner­ship with Roche, CF Foun­da­tion — plus some ion chan­nel tech once owned by Pfiz­er

6 years ago
Deals

No­var­tis nabs pri­or­i­ty re­view for a block­buster-to-be aimed at NSCLC niche — de­light­ing In­cyte ex­ecs

6 years ago
FDA+

Mod­er­na eyes $500M sec­ondary of­fer­ing on up­beat coro­n­avirus vac­cine up­date — al­most ready for the clin­ic

6 years ago
Deals
Coronavirus

Bio­haven's re­for­mu­lat­ed ALS drug is a flop in anx­i­ety, un­nerv­ing in­vestors ahead of CGRP mi­graine de­ci­sion

6 years ago
R&D

Fo­cus­ing on ge­net­i­cal­ly de­fined pop­u­la­tion still could­n't save Eli Lil­ly, Roche's an­ti-amy­loid Alzheimer's drugs

6 years ago
R&D

Record lev­els of VC fi­nanc­ing and R&D boom left bio­phar­ma com­pa­nies clam­or­ing for space. How bad is it?

6 years ago
Pharma

End­ing four years of le­gal fight, ARCH-backed syn­thet­ic DNA mak­er set­tles law­suit with CEO's for­mer em­ploy­er

6 years ago
FDA+

Par­ty on: Base edit­ing start­up, com­pu­ta­tion­al drug dis­cov­ery ex­perts and CRO bag close to $2B to­tal on their way to ...

6 years ago
Financing

Re­al-world da­ta get re­al dol­lars: GV, Bain help in­fuse $100M in­to Ve­r­ana Health as prag­mat­ic tri­al space heats up

6 years ago
Financing

Chi­na re­searchers tout in vit­ro da­ta for Gilead­'s an­tivi­ral against Wuhan virus — which they are try­ing to patent

6 years ago
China

HIV vac­cine re­mains Holy Grail as Sanofi/GSK reg­i­men dis­ap­points in large study

6 years ago
R&D

F-Prime backs a niche AI soft­ware start­up hunt­ing lofty goals in $22M Se­ries B

6 years ago
Financing
Startups

How much does it cost to boot­strap a gene ther­a­py start­up? Not too much if you're Jim Wil­son, per Pas­sage Bio's $125M ...

6 years ago
Financing
Cell/Gene Tx

Pan­dem­ic fears force Chi­nese biotech to post­pone Hong Kong IPO meet­ings — Bloomberg

6 years ago
Financing
China
First page Previous page 81828384858687 Next page Last page
A service from the Financial Times